华兰生物工程股份有限公司 独立董事候选人声明与承诺 声明人张志谦作为华兰生物工程股份有限公司第 9 届董事会独立董事 候选人，已充分了解并同意由提名人华兰生物工程股份有限公司董事会提名 为华兰生物工程股份有限公司（以下简称该公司）第 9 届董事会独立董事 候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的 关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事 项： 一、本人已经通过华兰生物工程股份有限公司第9届董事会提名委员会或 者独立董事专门会议资格审查，提名人与本 人不存在利害关系或者其他可能 影响独立履职情形的密切关系。 √是 □否 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 √是 □否 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定的独立董事任职资格和条件。 √是 □否 四、本人符合该公司章程规定的独立董事任职条件。 √是 □否 五、本人已经参加培训并取得证券交易所认可的相关培训证明材料（如有）。 √是 □否 六、本人担任独 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-044 经总经理提名，聘任李萍女士为公司财务总监，简历详见附件。李萍女士的 任职资格已经董事会审计委员会和提名委员会审核通过，符合相关法律法规规定 的任职条件，任期自本次董事会审议通过之日起至第九届董事会届满之日止。 特此公告。 华兰生物工程股份有限公司董事会 华兰生物工程股份有限公司 关于财务总监辞职暨聘任财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、财务总监辞职情况 华兰生物工程股份有限公司（以下简称"公司"）董事会于近日收到公司财 务总监谢军民先生的辞职报告，谢军民先生因工作调动原因申请辞去公司财务总 监，辞职后谢军民先生将会继续担任参股公司其他职务，其辞职报告自送达公司 董事会之日起生效。谢军民先生原定任期至公司第九届董事会任期届满时止。截 至本公告披露日，谢军民先生持有公司股份 1,313,380 股，辞职后其所持股份将 按照《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等相关 规定进行管理。 谢军民先生在担任公司财务总监期间，勤勉尽责、恪尽职守，公司 ...

华兰生物工程股份有限公司 独立董事提名人声明 提名人华兰生物工程股份有限公司董事会现就提名张志谦为华兰生物工 程股份有限公司第 9 届董事会独立董事候选人发表公开声明。被提名人已书面同 意作为华兰生物工程股份有限公司第 9 届董事会独立董事候选人（参见该独立董事 候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不 良记录等情况后作出的，本提名人认为被提名人符合 相关法律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过华兰生物工程股份有限公司第 9 届董事会提名委员 会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他 可能影响独立履职情形的密切关系。 √是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 √是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 √ ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-041 华兰生物工程股份有限公司 关于独立董事辞职暨补选第九届董事会 独立董事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于独立董事辞职的情况说明 华兰生物工程股份有限公司（以下简称"公司"）董事会于近日收到公司独 立董事王云龙先生提交的书面辞职报告。王云龙先生因个人原因申请辞去公司独 立董事、提名委员会、审计委员会委员职务。根据相关法律法规，王云龙先生的 辞职报告将在公司股东会选举产生新任独立董事后生效。 公司独立董事王云龙先生的辞职生效后，其在第九届董事会各专门委员会中 的空缺（第九届董事会提名委员会、审计委员会委员职务）将由张志谦先生接替， 鉴于张志谦先生目前为公司独立董事候选人，尚未当选独立董事，故该事项尚需 经股东会审议通过《关于补选第九届董事会独立董事的议案》方可生效，委员任 期自股东会审议通过之日起至第九届董事会届满之日止。 调整生效后公司第九届董事会各专门委员会的人员构成如下： | 专门委员会名称 | 成员 | 召集人（主任委员） | | ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-045 华兰生物工程股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 （1）截止 2025 年 11 月 10 日下午收市时，在中国证券登记结算有限责任公司深圳分公司登记在册的本 公司全体股东有权出席股东会，并可以书面形式委托代理人出席会议和参加表决，该股东代理人不必是 本公司股东，或在网络投票时间内参加网络投票。 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-039 华兰生物工程股份有限公司 关于第九届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物工程股份有限公司（以下简称"公司"）第九届董事会第三次会议 于 2025 年 10 月 17 日以电话或电子邮件方式发出通知，于 2025 年 10 月 29 日在 公司三楼办公室以通讯表决的方式召开。会议由公司董事长安康先生主持。会议 应到董事 9 名，实到董事 9 名。会议符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 王云龙先生因个人原因申请辞去公司独立董事、提名委员会委员、审计委员 会委员职务，辞去上述职务后，王云龙先生不在公司担任任何职务。王云龙先生 的原定任期至公司第九届董事会任期届满之日止，王云龙先生的辞职报告将在公 司股东会选举产生新任独立董事后生效。 经公司提名委员会及董事会审核，公司董事会同意补选张志谦先生为公司第 九届董事会独立董事，任期自股东会审议通过之日起至第九届董事会任期 ...

Group 1 - The core viewpoint of the article highlights that Hualan Biological's third-quarter revenue decreased by 14.00% to 1.581 billion yuan, while net profit fell by 44.45% to 269 million yuan [1] - For the first three quarters, the company's revenue was 3.379 billion yuan, representing a decline of 3.20%, and net profit was 784 million yuan, down 15.07% [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 1,580,688,450.84, representing a decrease of 14.00% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 268,563,529.57, down 44.45% year-on-year[5] - Basic earnings per share decreased by 44.64% to CNY 0.1467[5] - Total operating revenue for the current period is ¥3,378,886,377.05, a decrease of 3.2% from ¥3,490,648,261.92 in the previous period[18] - Net profit for the current period is ¥827,700,992.33, down 18.1% from ¥1,011,158,954.78 in the previous period[19] - Basic earnings per share for the current period is ¥0.4291, down from ¥0.5056 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 16,267,369,607.56, a slight decrease of 0.26% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to CNY 16,267,369,607.56, a slight decrease from CNY 16,309,951,355.29 at the beginning of the period[15] - Current assets increased to CNY 10,048,714,890.01 from CNY 9,616,191,068.19, reflecting a growth of approximately 4.5%[15] - Total liabilities increased to CNY 3,017,772,127.88 from CNY 2,463,225,371.87, marking an increase of about 22.5%[16] - The company's equity decreased to CNY 13,249,597,479.68 from CNY 13,846,725,983.42, reflecting a decline of approximately 4.3%[16] Cash Flow - Cash flow from investment activities increased by 3871.86% year-on-year, mainly due to a decrease in cash paid for investments[11] - The net cash flow from operating activities is ¥450,628,814.59, slightly down from ¥459,709,426.55 in the previous period[20] - Cash inflow from investment activities decreased to ¥9,673,231,639.89 from ¥18,045,530,207.37 in the previous period[20] - Cash outflow for investment activities was ¥8,936,858,346.82, compared to ¥18,026,990,442.39 in the previous period[20] - Net cash flow from financing activities was -859,196,666.44, compared to -627,795,396.80 in the previous period, indicating a decline in financing activities[21] - The cash and cash equivalents at the end of the period reached 1,686,241,001.06, an increase from 839,732,455.35 at the end of the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 147,902[10] - Cash dividends and interest payments totaled 390,198,653.05, showing the company's commitment to returning value to shareholders[21] Expenses and Financial Ratios - The company's weighted average return on equity was 2.25%, down 1.91% from the previous year[5] - The company experienced a 91.35% increase in financial expenses compared to the same period last year, attributed to reduced interest income[11] - Other income decreased by 55.07% year-on-year, primarily due to a reduction in government subsidies received[11] - The company reported a decrease in research and development expenses to ¥234,642,551.42 from ¥211,913,321.30 in the previous period, indicating a focus on innovation[18] Debt and Obligations - The company reported a 50.32% reduction in short-term borrowings compared to the beginning of the year, primarily due to repayment of maturing credit loans[11] - Short-term borrowings decreased significantly to CNY 447,000,000.00 from CNY 899,730,000.00, a reduction of about 50.3%[16] - The company incurred 1,179,380,000.00 in cash payments for debt repayment, indicating significant debt obligations[21] Accounting and Reporting - The company did not undergo an audit for the third quarter financial report, which may affect the perception of financial reliability[22] - The new accounting standards will be implemented starting in 2025, which may impact future financial reporting[23]

Core Viewpoint - The upcoming flu season in 2025 is expected to be significant, with a different strain circulating compared to last year, leading to lower immunity among the public. Vaccination remains the most effective preventive measure, and there is a noticeable increase in vaccine demand across various regions [1][4][5]. Vaccine Supply and Demand - There is a surge in flu vaccine demand, particularly among parents for their children, leading to situations where appointments are available but vaccines are not [6][8]. - The government procurement price for trivalent vaccines has dropped to a historical low of 5.5 yuan per dose, while the price of quadrivalent vaccines has remained stable [2][12]. - Sanofi, a major overseas player, has resumed supply to the Chinese market after a 10-month hiatus, but this has not significantly impacted the market dynamics as domestic manufacturers continue to dominate [10][11]. Flu Activity and Trends - The flu season may start earlier than in previous years, with reports indicating an increase in flu cases, particularly in southern provinces [3][4]. - The predominant strain this year is H3N2, which poses a higher risk due to lower public immunity compared to last year's H1N1 strain [4][5]. Pricing Dynamics - The price of trivalent vaccines has decreased significantly, while quadrivalent vaccines have stabilized after a previous price war [12][13]. - The procurement prices for government-subsidized vaccines have varied, but the overall trend indicates a potential for future price adjustments due to market conditions [13][14]. Market Competition - The return of Sanofi to the Chinese market raises questions about competitive dynamics, but domestic manufacturers like Sinopharm, Beijing Kexing, and Hualan Biological remain the primary suppliers [10][11]. - The flu vaccine market is characterized as an incremental market with substantial demand, and companies do not view each other strictly as competitors [11]. Recommendations for Public Health - Health authorities continue to recommend annual flu vaccinations as the best preventive measure, alongside personal hygiene practices [5][6]. - Increased public awareness and education about the importance of flu vaccination are essential for improving vaccination rates [13].

Core Points - The restructuring protein concept declined by 1.15%, ranking among the top declines in concept sectors as of the market close on October 23 [1] - Within the restructuring protein sector, major declines were observed in companies such as Haitai Biological, Maiwei Biological, and Yipinhong, while 14 stocks experienced price increases, with *ST Suwu, *ST Wanfang, and Kefu Medical leading the gains at 5.21%, 4.99%, and 2.90% respectively [1] Market Performance - The top-performing concept sectors today included Shenzhen State-Owned Enterprise Reform with a rise of 6.62%, while the restructuring protein sector faced a decline of 1.15% [2] - The restructuring protein sector saw a net outflow of 476 million yuan, with 37 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 30 million yuan [2] - Maiwei Biological led the net outflow with 69.48 million yuan, followed by Hualan Biological, BeiDa Pharmaceutical, and Zhifei Biological with outflows of 66.43 million yuan, 54.42 million yuan, and 33.70 million yuan respectively [2] Stock Performance - The top stocks with significant net outflows in the restructuring protein sector included: - Maiwei Biological: -5.53% with a turnover rate of 7.46% and a net outflow of 69.48 million yuan - Hualan Biological: -1.41% with a turnover rate of 1.37% and a net outflow of 66.43 million yuan - BeiDa Pharmaceutical: -3.26% with a turnover rate of 1.78% and a net outflow of 54.42 million yuan [3] - Conversely, the stocks with notable net inflows included: - SanSheng Guojian: +0.67% with a net inflow of 40.98 million yuan - Baipu Sais: +0.17% with a net inflow of 12.23 million yuan - Huiyu Pharmaceutical: +2.96% with a net inflow of 5.71 million yuan [4]